Khmamouche Mohamed Reda, Mahfoud Tarik, Bazine Aziz, Tanz Rachid, Ichou Mohamed, Errihani Hassan
Department of Medical Oncology, Military Hospital Mohamed V, Al Irfane, Hay Riad, Rabat, Morocco.
Department of Medical oncology, National institute of Oncology, Al Irfane, Hay Riad, Rabat, Morocco.
Pan Afr Med J. 2016 Oct 26;25:118. doi: 10.11604/pamj.2016.25.118.2266. eCollection 2016.
Colorectal cancer is one of the most common cancers worldwide, and associated with high mortality rates in our country. The prognosis of patients diagnosed with metastatic colorectal cancer (mCRC) has improved markedly over the last 12 years, increasing from 5 months with best supportive care to almost 2 years with combination chemotherapy plus bevacizumab. Bevacizumab is well suited for use in combination with first or second line chemotherapy in the treatment of mCRC because its side effects are predictable and appear not to add to the incidence or severity of the side effects of chemotherapy. The aim of our small study is to explore the tolerability profile of bevacizumab used in daily clinical practice in patients with metastatic colorectal cancer (mCRC) in our department.
结直肠癌是全球最常见的癌症之一，在我国其死亡率也很高。在过去12年中，被诊断为转移性结直肠癌（mCRC）患者的预后有了显著改善，从单纯最佳支持治疗时的5个月提高到联合化疗加贝伐单抗治疗后的近2年。贝伐单抗非常适合与一线或二线化疗联合用于治疗mCRC，因为其副作用是可预测的，而且似乎不会增加化疗副作用的发生率或严重程度。我们这项小型研究的目的是探讨在我们科室转移性结直肠癌（mCRC）患者的日常临床实践中使用贝伐单抗的耐受性情况。
